British Journal of Cancer - PARP inhibitors: the race is on

PARP inhibitors: the race is on

 A number of other critical questions remain in terms of optimising and widening the clinical efficacy and utility of PARP inhibitors, respectively. Although benefits are observed following PARP inhibitor treatment in patients with a range of tumour types with germline BRCA1/2 mutations (Kaufman et al., 2015), it is now clear that clinical efficacy is not restricted to this niche population of patients.

Table 1 - Table showing the response rates and predominant toxicities for different PARP inhibitors in patients with advanced ovarian cancer.